{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-024801","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2022-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.455016+00:00","generated_at":"2026-06-23T00:44:57.292854+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"FDA maintains clinical hold on DiaMedica's ReMEDy2 stroke trial; cash $36.1M","bullets":["FDA requires additional in-use IV stability study (tubing + pump) to lift clinical hold on Phase 2/3 ReMEDy2 trial.","Cash, equivalents, and marketable securities were $36.1M as of Sept 30, 2022; Q3 cash burn $2.3M.","Company will request Type A FDA meeting to confirm study design and gain guidance toward resumption.","Three transient hypotension cases led to hold; all patients recovered without lasting effects."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-024801","json":"https://secwatch.observer/filing/0001437749-22-024801.json","markdown":"https://secwatch.observer/filing/0001437749-22-024801.md","text":"https://secwatch.observer/filing/0001437749-22-024801.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774922024801/0001437749-22-024801-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774922024801/dmtp20221026_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T00:44:57.292854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}